Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

By Ludwig Burger (Reuters) -French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in ...

PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...

Sanofi is now in “exclusive negotiations ... With the French government saying that it has received assurances from New York City-based CD&R that it will keep Opella’s manufacturing facilities ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

French pharmaceutical company Sanofi confirmed on Monday its plans to sell a controlling stake in its consumer health unit Opella to a US investment fund, after providing the French government ...

The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier ...

French healthcare company Sanofi has decided to halt work on its once praised breast cancer medication amcenestrant after a second failed clinical trial. A possible new coronavirus vaccine ...

MC: There is no old or new model, but there is old school thinking and open school thinking. We are clearly conscious of this within Sanofi and we truly believe that we will overcome the future ...

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

The European Union's CHMP has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’ Wainzua to treat ATTRv-PN.